NRSN
NeuroSense Therapeutics Ltd.·Healthcare
0.91
4.530%(+0.04)
Market OpenLast Updated: — ET
52W L: $0.6352W H: $2.60
NRSN NEWS
prnewswire.com
Apr 28
NeuroSense Announces Pricing of Insider-Led PIPE Financing
Financing led by CEO Alon Ben-Noon and CFO Or Eisenberg, alongside participation from an existing significant shareholder CAMBRIDGE, Mass., April 28, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
defenseworld.net
Apr 7
Brokerages Set NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Price Target at $8.50
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one
prnewswire.com
Apr 6
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
Patent Protection Through October 2042 Follows prior patent grants in the U.S. and Australia Further strengthens NeuroSense's global intellectual property portfolio CAMBRIDGE, Mass., April 6, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
prnewswire.com
Apr 3
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
Notifications have no immediate effect on the listing or trading of the Company's securities on Nasdaq Nasdaq has provided the Company until September 29, 2026 to regain compliance with both requirements The Company is actively evaluating actions to regain compliance, with a clear focus on initiatives that are aligned with and supportive of long-term shareholder value CAMBRIDGE, Mass., April 3, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
prnewswire.com
Mar 31
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program in ALS Statistically significant survival benefit demonstrated, including 65% reduction in risk of death and >14-month median survival advantage Results published in JAMA Neurology, providing high-level peer-reviewed validation of clinical and biological activity Advancing toward key regulatory milestones with planned pre-NDS meeting in Canada and near-term Alzheimer's readout CAMBRIDGE, Mass., March 31, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
prnewswire.com
Mar 24
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
